Fierce Pharma
APRIL 25, 2024
After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin. | After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin.
MedCity News
APRIL 25, 2024
Regeneron Pharmaceuticals is collaborating with CRISPR technologies startup Mammoth Biosciences to develop in vivo gene-editing therapies. The deal marks the third pharmaceutical industry partnership for Mammoth, which initially focused on developing CRISPR-based diagnostics. The post Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
APRIL 25, 2024
For the first time in more than 20 years, the FDA has approved a | For the first time in more than 20 years, the FDA has approved a treatment for uncomplicated urinary tract infections. And the endorsement has come for an oral antibiotic that has been available in Europe for more than 40 years. It’s an odd set of circumstances and a dose of foresight by Utility Therapeutics that bring Pivya (pivmecillinam) to the market in the United States in the therapy’s golden years.
MedCity News
APRIL 25, 2024
Walgreens announced that it is expanding its specialty pharmacy offerings. Experts think that this move could yield several strategic benefits, given the higher profit margins associated with specialty medications compared to traditional drugs. They also think Walgreens’ move could lead to greater competition, consolidation and innovation within the broader pharmacy industry.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
APRIL 25, 2024
Just a few months after laying into CEOs from Bristol Myers Squibb, Merck & Co., and Johnson & Johnson about the high costs of their drugs, Sen. | Just a few months after laying into CEOs from Bristol Myers Squibb, Merck & Co. and Johnson & Johnson about the high costs of their drugs, Sen. Bernie Sanders, I-Vermont, is taking Novo Nordisk to task for allegedly turning its blockbuster GLP-1s Ozempic and Wegovy into “luxury goods.
European Pharmaceutical Review
APRIL 25, 2024
Four key barriers to female career progression were explored during a panel at the UK 2024 Advanced Therapies conference in March. Hosted by members of the professional women’s networking group CGT Circle, the session explored factors that could be contributing to the current imbalance for women in leadership positions within the cell and gene therapy (CGT) sector.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
APRIL 25, 2024
People do not have to die waiting for a kidney. A VBC approach can lead to earlier identification of kidney disease and better management in its earlier stages. The post With All the Organ Donation Scrutiny, Ask: What Can We Do to Reduce the Need? appeared first on MedCity News.
Fierce Pharma
APRIL 25, 2024
Where innovation meets obstacles and the cost of drug development skyrockets, the key to unlocking success of groundbreaking products in the biopharma industry will rely heavily on strategic | Collaborative partnerships key to clearing the path for new biopharma products
European Pharmaceutical Review
APRIL 25, 2024
Research on the global pharmaceutical parenteral packaging market by InsightAce Analytic Pvt. Ltd. has predicted that the sector will value $18.85 billion by 2031. This is aligned with a CAGR of 4.47 percent between 2024 and 2031. Main drivers for the market were reported to be rising popularity of generics together with blockbuster and other small-molecule drugs going off-patent globally.
Fierce Pharma
APRIL 25, 2024
Facing pressure from the Inflation Reduction Act (IRA) and falling sales for CAR-T therapy Abecma, Bristol Myers Squibb CEO Chris Boerner, Ph.D., still says the Breyanzi-maker h | Facing pressure from the Inflation Reduction Act and falling sales for CAR-T therapy Abecma, Bristol Myers Squibb CEO Chris Boerner says the Beyenzi-maker had a "good start" with the first quarter.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
European Pharmaceutical Review
APRIL 25, 2024
A study has determined that for biologics subject to multiple stresses during bioprocessing and manufacturing , “exposure to air-liquid interfacial dilatational stress is the predominant mechanism impacting protein particle formation, [both] at the interface and in the bulk solution” Researchers established a “unique” set-up using a peristaltic pump and a Langmuir-Pockels trough to study the impact of hydrodynamic shear stress due to pumping and interfacial dilatational stress, on the form
Fierce Pharma
APRIL 25, 2024
Novartis has started cutting ties with Chinese contractors amid a potential threat from the BIOSECURE Act. | Novartis has started cutting ties with Chinese contractors amid a potential threat from the BIOSECURE Act. A depression drug candidate that Neurocrine licensed from Takeda succeeded in a phase 2 trial. AstraZeneca and Daiichi Sankyo's Enhertu is on the cusp of a key readout in HER2-low breast cancer.
MedCity News
APRIL 25, 2024
How health tech startups can successfully adapt the principles to their business ideas The post Examining the Usefulness of the Lean Startup Method in Building Health Tech Products appeared first on MedCity News.
Fierce Pharma
APRIL 25, 2024
Joining a list that recently includes Pfizer, UCB and WuXi AppTec, Takeda Pharmaceuticals is the latest drugmaker to pull out of prominent industry lobbying group the Biotechnology Innovation Organ | The company opted not to renew its Biotechnology Innovation Organization (BIO) membership for its next fiscal year.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Commerce
APRIL 25, 2024
The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.
Fierce Pharma
APRIL 25, 2024
Even as new Sanofi drugs like Beyfortus and Altuviiio come into their own, the French pharma’s immunology powerhouse Dupixent shows no signs of slowing down. | Even as new Sanofi drugs like Beyfortus and Altuviiio come into their own, the French pharma’s immunology powerhouse Dupixent shows no signs of slowing down. In fact, Sanofi is already gearing up for the antibody’s potential debut in what CEO Paul Hudson dubbed the drug’s “next major growth pillar.
Pharmaceutical Technology
APRIL 25, 2024
Marking another chapter in the long-running saga, J&J has deprioritised the CD388 influenza programme allowing Cidara to buy it back.
Fierce Pharma
APRIL 25, 2024
Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. | This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Staff Writer Kevin Dunleavy are diving into our annual top pharma companies by revenue special report.
PharmaTimes
APRIL 25, 2024
The tool will help people find out about clinical trials for myeloma, MGUS, SMM and AL amyloidosis
Fierce Pharma
APRIL 25, 2024
Navigating the Impact of the Inflation Reduction Act: Assessing Current Realities and Future Trajectory jpiatt Thu, 04/25/2024 - 14:30
PharmaTimes
APRIL 25, 2024
X-linked Charcot-Marie-Tooth is the second most common form of the rare peripheral neuropathy disease
MedCity News
APRIL 25, 2024
If you advise self-insured employers on healthcare benefits, your expert insights will help provide a comprehensive perspective of the state of healthcare benefits for employers in our second annual survey, the 2024 Benefit Consultant Sentiment THE INDEX. The post Which AI Applications Interest Your Employer Clients the Most? Where Will They Have the Greatest Impact?
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Clarivate
APRIL 25, 2024
Sustainability has become increasingly critical for organizations to demonstrate their missions and address some of the world’s most pressing challenges. Much like digital transformation, driving sustainability requires organizations to transform every division of their business and integrate in the corporate strategy. As part of the 2030 Agenda for Sustainable Development, the United Nation (UN) has outlined seventeen Sustainable Development Goals (SDGs) as a blueprint for peace and prosperity
MedCity News
APRIL 25, 2024
Embedding patient financing options into the billing process presents a very clear solution for providers and patients to balance affordability and increase collectability. The post Debunking the Myths Around Patient Financing appeared first on MedCity News.
Pharmaceutical Commerce
APRIL 25, 2024
The latest news for pharma industry insiders.
Pharmaceutical Technology
APRIL 25, 2024
Merck has announced an investment of more than €300m ($320.8m) in a new Life Science Research Center at its global headquarters in Darmstadt, Germany.
PharmaTech
APRIL 25, 2024
Continuous Manufacturing in pharmaceuticals can increase process understanding while overcoming disadvantages of batch manufacturing: slow and expensive development and tech transfer, plus inefficiencies, product loss, and human error in commercial manufacturing.
Referral MD
APRIL 25, 2024
Healthcare technology has reached new heights with ReferralMD’s game-changing Digital Front Door solution , powered by cutting-edge conversational AI. This innovative approach aims to reshape the patient experience and streamline administrative processes, marking a significant leap forward for healthcare providers and patients. ReferralMD sets itself apart in a competitive landscape by offering a comprehensive platform encompassing Digital Front Door , eConsults, Referral Management , Fax
PharmaTech
APRIL 25, 2024
Compliance and quality are not the same thing. While compliance means manufacturers demonstrate they meet regulatory requirements, quality is foundational to patients’ confidence in the safety and effectiveness of their medications.
PharmExec
APRIL 25, 2024
In this Pharmaceutical Executive video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but address their specific healthcare needs
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
253 
Let's personalize your content